Email this article DEVELOPMENT OF A CANDIDATE SYNTHETIC VACCINE FOR IMMUNOTHERAPY OF MELANOMA
- Authors: Borobova E.A.1, Antonets D.V.1, Starostina E.V.1
-
Affiliations:
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector»
- Issue: Vol 22, No 2-2 (2019)
- Pages: 1003-1005
- Section: ORIGINAL ARTICLES
- URL: https://rusimmun.ru/jour/article/view/446
- DOI: https://doi.org/10.31857/S102872210006491-5
- ID: 446
Cite item
Full Text
Abstract
Melanoma is the most dangerous skin cancer. It’s characterized by rapid growth rates and high incidences of metastasis. Melanoma cells have tumor antigens on their surfaces. Thereby, it’s possible to create an eff ective vaccine against melanoma. Earlier in the Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector» DNA-constructs, encoding artifi cial polyepitope immunogens MEL-A0201 and MEL-TCI, that consist of cytotoxic and helper T-cell epitope form six melanoma antigens, were created. This article includes the results of evaluation of the capability of designed DNA-constructs to induce antitumor immune response.
About the authors
E. A. Borobova
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector»
Author for correspondence.
Email: borobova-elena@rambler.ru
researcher,
Koltsovo, Novosibirsk region
Russian FederationD. V. Antonets
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector»
Email: fake@neicon.ru
PhD, senior researcher,
Koltsovo, Novosibirsk region
Russian FederationE. V. Starostina
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology «Vector»
Email: fake@neicon.ru
researcher,
Koltsovo, Novosibirsk region
Russian FederationReferences
- Siegel R, Miller K, Jemal A. Cancer Statistics, 2018. Ca-a Cancer Journal for Clinicians. 2018, 68(1), 7–30. doi: 10.3322/caac.21442.
- Pitcovski J., Shahar E., Aizenshtein E, Gorodetsky R. Melanoma antigens and related immunological markers. Critical Reviews in Oncology/Hematology. 2017, Vol. 115, P. 36–49.
- Liu M. DNA vaccines: an historical perspective and view to the future. Immunological reviews. 2011. Vol. 239. P. 62–84
- Боробова Е. А., Антонец Д. В., Старостина Е. В., Смирнова О. Ю., Щербаков Д. Н., Волкова О. Ю., Орешкова С. Ф., Карпенко Л. И., Ильичев А. А., Бажан С. И. Кандидаты ДНК-вакцины против меланомы: дизайн, конструирование и оценка экспрессии целевых генов в эукариотических клетках. Новосибирский государственный университет. 2012, 10(5), 23–30.
- Park M., Yang D., Kim M., Jang J., Jang Y., Lee Y., Jin C., Pham T., Thi T., Lim M., Lee H., Hong C., Yoon J., Lee J. Alpha-type 1 polarized dendritic cells loaded with apoptotic allogeneic breast cancer cells can induce potent cytotoxic t lymphocytes against breast cancer. Cancer Res Treat. 2011, 43(1), 56–66.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).